CA
SEEL

Cliff Asness’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Cliff Asness’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25
Closed -$156K – 2313
2021
Q4 		$156K Buy
+25
New +$192K ﹤0.01% 2118

Other funds holding SEEL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $1.07B AUM 34.04% 1-Year Est. Return

Cliff Asness's SEEL Position: Q1 2022 in Review

Cliff Asness sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2022, closing a stake of 25 shares — an estimated $156K sold.

Cliff Asness first reported a position in SEEL in Q4 2021 and held it in 1 quarter. The position peaked at $156K in Q4 2021. 77 funds tracked by Wall St. Rank hold SEEL as of Q1 2022.

  • Cliff Asness reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Cliff Asness sold 25 Seelos Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $156K.
  • Cliff Asness first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Cliff Asness's Seelos Therapeutics, Inc. Common Stock position peaked at $156K in Q4 2021.
  • 77 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2022.

Based on AQR Capital Management's 13F filing for Q1 2022, filed 16 May 2022.